MDE (3,4-Methylenedioxyethamphetamine, "Eve")

Index

   Index ('round and 'round we go...) 
   Chemical Structure 
   Synonyms 
   Physical Properties 
   Scheduling 
   References 
      Review Articles 
      Hyperthermic Reactions 

Chemical Structure

    O   /\\  /\  NHCH2CH3
   / \ /  \\/  \/
  /   ||   |    |
CH2   ||   |    |
  \   ||   |    CH3
   \ / \  //
    O   \//

C12H17NO2 

Synonyms

Common Chemical Name: 
   3,4-Methylenedioxyethamphetamine 
Common Chemical Abbreviation: 
   MDE, MDEA, N-Ethyl-MDA 
Chemical Abstracts: 
   1,3-Benzodioxole-5-ethanamide, N-ethyl-alpha-methyl- (Current) 

   [14089-52-2] MDE (unspecified) 
   [743-78-9]   MDE HCl 
         

DEA Drug Control Numbers: 

   7404: MDE

Edgewood Arsenel: 
Merck: 
   None 
All Chemical Names: 
   3,4-Methylenedioxyethamphetamine (common) 
   3,4-Methylenedioxyethylamphetamine (common) 
   N-Ethyl-3,4-methylenedioxyamphetamine (common) 
   N-Ethyl-3,4-methylenedioxyphenylisopropylamine (common) 
   N-Ethyl-1-(3,4-methylenedioxyphenyl)-2-propanamine 
   2-Ethylamino-1-(3,4-methylenedioxyphenyl)-propane 
   N-Ethyl-beta-(3,4-methylenedioxyphenyl)-isopropylamine 
   N-Ethyl-alpha-methyl-beta-(3,4-methylenedioxyphenyl)-ethylamine 
   N-Ethyl-alpha-methyl-3,4-methylenedioxyphenethylamine 
   N-Ethyl-alpha-methylhomopiperonylamine 
   N-Ethyl-alpha-methylbenzodioxole-5-ethanamide (common) 
All Chemical Abbreviations: 
   MDE, MDEA, N-Ethyl-MDA 
Unofficial/Street Names: 
   Eve, (commonly misrepresented as MDMA -- see Street Names for MDMA) 

Physical Properties

Melting Points: 
Index of Refraction: 

Scheduling

   US: 
      13 Aug 1987 -- Proposed Schedule I (52 FR 30175) 
      15 Oct 1987 -- Start of One-Year Emergency Scheduling (52 FR 38225) 
      15 Oct 1988(?) -- Permanent Schedule I status (??????) 
   UK: 

References

NOTE: MDE is more or less similar enough to MDMA that many of the references will be applicable, although care must be taken in making generalizations.

Review Articles

   Dal Cason-TA. "An Evaluation of the Potential for Clandestine Manufacture of 3,4-Methylenedioxyamphetamine (MDA) Analogs and Homologs." Journal of Forensic Sciences. Vol 35(3):675-697.
   May 1990.

      This is the article to read for anybody who is interested in the different methods of synthesizing methoxylated amphetamines. It is, however, a little bit on the technical side. 

   Buchanan-JF, Brown-CR. "'Designer Drugs': A problem in Clinical Toxicology." Medical Toxicology. Vol 3:1-17. 1988.

      Starts: "Contrary to the popular belief that 'designer drugs' are original creations, the majority... are 'borrowed' from legitimate pharmaceutical research." It then launches into an
      overview of the toxicology of: amphetamines, TMA, DOM, PMA, DOB, 2C-B, MDA, MDMA, MDE, Fentanyl, Meperidine, MPTP, PCP analogues and Methaqualone derivatives. 

Hyperthermic Reactions

   NOTE: See the file on MDMA for more information on hyperthermic reactions to entactogens.

   Tehan-B, Hardern-R, Bodenham-A. "Hyperthermia associated with 3,4-methylenedioxyethamphetamine ('Eve')." Anaesthesia. Vol 48:507-510. 1993.

      A case of MDE hyperthermia is presented. "...caffiene and halothane contractive tests for malignant hyperthermia susceptibility were negative." This would tend to refute the notion that
      an ideosynratic reaction was responsible as strongly suggested by Larner in the Sep 19 1992 Lancet. Also notes that "active cooling measures alone failed to lower body temperature"
      which may imply that the notion that ambient temperature is critically involved in producing MDMA hyperthermia is wrong. Much discussion is given to the technical details of treating
      hyperthermic MDMA users.


April 14, 1994 | lamontg@u.washington.edu 
